Literature DB >> 8421287

1,3-dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes.

H O Kim1, R F Schinazi, S Nampalli, K Shanmuganathan, D L Cannon, A J Alves, L S Jeong, J W Beach, C K Chu.   

Abstract

In order to study the structure-activity relationships of dioxolane nucleosides as potential anti-HIV-1 agents, various enantiomers of pure dioxolanylpurine nucleosides were synthesized and evaluated against HIV-1 in human peripheral blood mononuclear cells. The enantiomerically pure key intermediate 1, which was synthesized in nine steps from 1,6-anhydro-beta-D-mannose, was condensed with 6-chloropurine, 6-chloro-2-fluoropurine, and 2,6-dichloropurine in the presence of TMS triflate. The chloro or fluoro substituents were readily converted into amino, N-methylamino, hydroxy, methoxy, thiol, and methylthio under appropriate reaction conditions. Upon evaluation of these dioxolanes, the guanine derivative 24 exhibited the most potent anti-HIV-1 activity without cytotoxicity up to 100 microM in various cells. The decreasing antiviral activity order of beta-isomers was as follows: guanine > 6-chloro-2-aminopurine > 2-fluoroadenine > or = adenine > or = 2,6-diaminopurine > hypoxanthine > 2-chloroadenine > 6-chloropurine approximately equal to N6-methyladenine approximately equal to 6-mercaptopurine approximately equal to 6-(methylthio)purine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8421287     DOI: 10.1021/jm00053a004

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

1.  Adenosine Dioxolane Nucleoside Phosphoramidates as Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses.

Authors:  Lavanya Bondada; Mervi Detorio; Leda Bassit; Sijia Tao; Catherine M Montero; Tyana M Singletary; Hongwang Zhang; Longhu Zhou; Jong-Hyun Cho; Steven J Coats; Raymond F Schinazi
Journal:  ACS Med Chem Lett       Date:  2013-08-08       Impact factor: 4.345

2.  Scaleable processes for the synthesis of (-)-β-D-2,6-diaminopurine dioxolane (Amdoxovir, DAPD) and (-)-β-D-2-aminopurine dioxolane (APD).

Authors:  Longhu Zhou; Steven J Coats; Hongwang Zhang; Shi Junxing; Drew R Bobeck; Raymond F Schinazi
Journal:  Tetrahedron       Date:  2012-05-16       Impact factor: 2.457

3.  Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.

Authors:  Z Gu; M A Wainberg; N Nguyen-Ba; L L'Heureux; J M de Muys; T L Bowlin; R F Rando
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Pharmacokinetics of (-)-beta-D-2-aminopurine dioxolane and (-)-beta-D-2-amino-6-chloropurine dioxolane and their antiviral metabolite (-)-beta-D-dioxolane guanine in rhesus monkeys.

Authors:  H Chen; F D Boudinot; C K Chu; H M Mcclure; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

5.  Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.

Authors:  Kirsten L White; Nicolas A Margot; Terri Wrin; Christos J Petropoulos; Michael D Miller; Lisa K Naeger
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

6.  In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.

Authors:  H Z Bazmi; J L Hammond; S C Cavalcanti; C K Chu; R F Schinazi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

7.  Novel use of a guanosine prodrug approach to convert 2',3'-didehydro-2',3'-dideoxyguanosine into a viable antiviral agent.

Authors:  Adrian S Ray; Zhenjun Yang; Chung K Chu; Karen S Anderson
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

8.  Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro.

Authors:  Cécile L Tremblay; Danielle L Poulin; Jennifer L Hicks; Subajini Selliah; Annie Chamberland; Françoise Giguel; Christopher S Kollmann; Ting Chao Chou; Huajin Dong; Martin S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

9.  Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients.

Authors:  Stephen Kewn; Laurene H Wang; Patrick G Hoggard; Franck Rousseau; Robert Hart; John P MacNeela; Saye H Khoo; David J Back
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs.

Authors:  Janarthanan Narayanasamy; Manik R Pullagurla; Ashoke Sharon; Jianing Wang; Raymond F Schinazi; Chung K Chu
Journal:  Antiviral Res       Date:  2007-03-30       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.